Scholarlink

<p>Paper substrates, with their inherent capillary-driven forces, eliminate the need for external power sources typically required by microfluidic biochips. However, conventional lateral flow (LF) systems face limitations, including non-specific adsorption, uneven molecular distribution, and restricted flexibility for multiplexed detection. In this work, we developed a novel vertical-flow paper-tape (VFPT) integrated device. By engineering a gradient pore-size paper substrate and replacing pre-patterned channels with gravity-driven flow, this innovation achieves size-selective molecular transport while doubling the effective transport distance. Its roll-to-roll fabrication process enables scalable, low-cost production with customizable detection capabilities. As a proof of concept, the VFPT device demonstrated detection limits of 200 copies/mL for HIV and HBV and 600 copies/mL for HCV, comparable to PCR and superior to traditional paper-based systems. Validation with 203 blinded clinical plasma samples revealed sensitivity and specificity exceeding 90.9%. This innovative platform offers a user-friendly, accurate, and cost-effective solution for clinical diagnostics and resource-limited settings.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Vertical-flow tearable paper-tape rolls for scalable multiplexed point-of-care nucleic acid testing

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月7日

查看全文
  • Shaorui Shi,
  • Zhiying Wang,
  • Yongchao Yao,
  • Yue Gao,
  • Jianchao Tang,
  • Chuyan Zhang,
  • Hao Bai,
  • Zhao Du,
  • Jie Hu,
  • Yue Su,
  • Guannan Chen,
  • Xinxia Cai,
  • Binwu Ying,
  • Lingqian Chang,
  • Wenchuang Hu,
  • Yang Wang

摘要

Paper substrates, with their inherent capillary-driven forces, eliminate the need for external power sources typically required by microfluidic biochips. However, conventional lateral flow (LF) systems face limitations, including non-specific adsorption, uneven molecular distribution, and restricted flexibility for multiplexed detection. In this work, we developed a novel vertical-flow paper-tape (VFPT) integrated device. By engineering a gradient pore-size paper substrate and replacing pre-patterned channels with gravity-driven flow, this innovation achieves size-selective molecular transport while doubling the effective transport distance. Its roll-to-roll fabrication process enables scalable, low-cost production with customizable detection capabilities. As a proof of concept, the VFPT device demonstrated detection limits of 200 copies/mL for HIV and HBV and 600 copies/mL for HCV, comparable to PCR and superior to traditional paper-based systems. Validation with 203 blinded clinical plasma samples revealed sensitivity and specificity exceeding 90.9%. This innovative platform offers a user-friendly, accurate, and cost-effective solution for clinical diagnostics and resource-limited settings.